Author pages are created from data sourced from our academic publisher partnerships and public sources.
Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
9008Background: ALK tyrosine kinase inhibitors (TKIs) are standard of care for patients (pts) with advanced ALK+ NSCLC, and preclinical data suggest potential synergistic activity with checkpoint i...
Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
- M. Atkins, S. Gupta, +7 authors E. Plimack
- Journal of Immunotherapy for Cancer
- 4 November 2015
Meeting abstracts Axitinib, an inhibitor of vascular endothelial growth factor receptors (VEGFRs), is approved for second-line treatment of advanced renal cell carcinoma (aRCC). Pembrolizumab is a… Expand
Syntheses of mono- and di-pyrenyl perfluoroalkanes
Abstract The syntheses of a series of fluorophores of the general formula: pyrene-(CF 2 ) n -pyrene ( n =3, 4 and 6) and pyrene-(CF 2 ) n -F ( n =4 and 6) are reported using two different… Expand
8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study
Development and validation of a prognostic nomogram for progression-free and overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib.
405 Background: Pazopanib, an oral multikinase inhibitor, demonstrated noninferiority to sunitinib in patients with aRCC in COMPARZ (NCT00720941), a randomized, phase III trial (NEJM 2013;369:722).… Expand
Abstract C71: Phase II study of maintenance therapy with pazopanib or pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following platinum-based…
- K. Konduri, D. Smith, Natalie Compton, Denise Elmore Lockheed, D. Chakrabarti, K. Bhatt
- 1 November 2013
Background: Platinum-based chemotherapy combinations are the standard of care in first-line treatment of advanced NSCLC. Maintenance therapy with a chemotherapeutic agent (continuation maintenance)… Expand
Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC).
329 Background: A randomised, double-blind phase II study of axitinib plus BSC [AXI] vs placebo plus BSC [PBO] was conducted in HCC pts after failure of one antiangiogenic therapy. Primary outcome… Expand
Development and internal validation of a prognostic nomogram for overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib (PAZ).
- D. Chakrabarti, K. Bhatt, F. Mehmud, C. Sternberg, R. Motzer
- Journal of clinical oncology : official journal…
- 20 February 2013
380 Background: PAZ, an oral multikinase inhibitor, demonstrated significant improvement in PFS over placebo in patients with aRCC in a randomized, phase III trial (J Clin Oncol 2009:29; 475). The… Expand
STUDY OF SOCIOECONOMIC IMPACT AFTER ONE YEAR OF ANTIRETROVIRAL THERAPY IN HIV INFECTED PATIENTS IN A TERTIARY CARE CENTRE IN NORTH BENGAL
Syntheses of Mono- and Di-pyrenyl Perfluoroalkanes.